Dade Behring Marburg Gmbh

Behringwerke Aktiengesellschaft

Behring Diagnostics Gmbh

Michael Kraus

Carsten Schelp

Andreas Wiegand

Werner Stuber

Thomas Wissel

Jurgen Romisch

Wilhelm Schuy

Werner St&uuml;ber

Heinz-Georg Kandel

Hermann Keuper

Hubert Nettelhoff

Heinz-Hermann Drescher

Erika Aillaud

Reiner Muth

The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

Method and diagnostic agent for hemostasis diagnosis

The present invention relates to procedures for the detection or for the determination of solid phase-associated factors, which are multiply associated with the same solid phase. According to the invention, the sample is brought into contact with a transmitter particle, on which at least one ligand having binding affinity for a solid phase-associated factor and a transmitter are immobilized, and a receiver particle, on which at least one ligand having binding affinity for said solid phase-associated factor and a receiver is immobilized, and then the signal is determined which results when transmitter and receiver are brought sufficiently close to one another. In particular, the invention relates to the detection of cell surface receptors which can be used for the typing of cells or for the determination of cell activation states. It is thus possible to replace the hitherto widely customary flow cytometry by a more simple procedure.

Detection and determination of solid phase-associated factors

The present invention is directed to the generation of antibodies which preferentially bind to fibrinogen fragments E1, E2 and E3, but exhibit little or no cross-reactivity against fibrin monomer and fibrinogen. Thus, the invention provides synthetic peptides containing defined amino acid sequences corresponding to the carboxy terminal regions of the E fragments which arise as a result of plasmin cleavage of fibrin and fibrinogen. The synthetic peptides may be synthesized chemically, or through genetic manipulations, and may contain additional amino acid sequences which are not contiguous with the defined E fragment sequences.

Synthetic peptides, antibodies against them and their use

The present invention relates to a process for increasing the FVII sensitivity of a thromboplastin reagent by means of heat treatment.

Increasing the FVII sensitivity of a thromboplastin reagent

The invention relates to a process for preparing factor V-deficient plasma, in particular a factor V-deficient plasma from a starting plasma using antibodies, and a deficient plasma which is obtained in this way.

Process for preparing factor V-deficient plasma, and a deficient plasma which is obtained in this way

The invention relates to a process for the production of plasmas with added annexins for use as a control or standard in all functional clotting tests which are used for the detection of a lupus anticoagulant.

Use of annexins as a lupus anticoagulant control or standard in clotting tests

The invention relates to a method for carrying out heterogeneous immunoassays, in particular to a method for separating a coated solid phase from a liquid phase by means of precipitation and subsequent centrifugation, with a detectable activity remaining in the liquid phase.

Heterogeneous immunoassay using a precipitable solid phase

Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state.

Method for specifically detecting a coagulation factor V which has an

The present invention is directed to the generation of antibodies which preferentially bind to fibrinogen fragments E1, E2, and E3, but exhibit little or no cross-reactivity against fibrin monomer and fibrinogen. Thus, the invention provides synthetic peptides containing defined amino acid sequences corresponding to the carboxy terminal regions of the E fragments which arise as a result of plasmin cleavage of fibrin and fibrinogen. The synthetic peptides may be synthesized chemically, or through genetic manipulations, and may contain additional amino acid sequences which are not contiguous with the defined E fragment sequences.

The invention relates to a plasma which can be used as a calibrator in coagulation tests which detect the degradation of factor V by activated protein C, to the preparation of such a plasma and to its use.

Calibrator for use in test methods for detecting a defective coagulation

The present invention relates to a method for detecting disturbances of the protein C/protein S system.

Method for detecting disturbances of the protein c/protein s system

The invention relates to antibodies which react with fibrinogen fragments E1, E2 and E3 raised by immunizing with a peptide. The invention also relates to assay methods for proteins containing an epitope which is common to fibrinogen fragments E1, E2 and E3 using these antibodies.

Antibodies which react with fibrinogen fragments E1, E2 and E3 and

The invention relates to a method for determining analytes, in which a sample of a biological material which possibly contains this analyte is incubated with at least one binding partner which is specific for the analyte and which is immobilized on a particulate carrier material, and the change in turbidity brought about by the analyte is determined.

Growing community of inventors

Marburg, Germany

Michael Kraus